NeuroBo Pharmaceuticals: First site IRB approval for Phase 2a trial of DA-1241

NeuroBo Pharmaceuticals announced that it has received the first site Institutional Review Board approval for Zeid Kayali, M.D., Medical Director at Inland Empire Liver Foundation, in Rialto, CA, to proceed with the Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist, for the treatment of nonalcoholic steatohepatitis. The dosing of the first patient in part one of the two-part, Phase 2a clinical trial of DA-1241 is expected to occur in September of 2023.